UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ☐ | Definitive Proxy Statement | |
| ☐ | Definitive Additional Materials | |
| ☒ | Soliciting Material under Rule 14a-12 | |
GW PHARMACEUTICALS PLC
(Name of Registrant as Specified In Its Charter)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. | |||
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid:
| |||
| ☐ | Fee paid previously with preliminary materials. | |||
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing Party:
| |||
| (4) | Date Filed:
| |||
Explanatory Note: The following communications were made available by Jazz Pharmaceuticals or its officers through various social media accounts.
Jazz Pharmaceuticals••• @JazzPharma Yesterday, Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, which will strengthen our position as an innovative global biopharma company by combining our strengths with an industry leader in #cannabinoid science. Important: bit.ly/3pOqBAU Jazz Pharmaceuticals 8:47 AM • Feb 4, 2021 â– Twitter Web App
Neena Patil General Counsel at Jazz Pharmaceuticals (NASDAQ; JAZZ) 2h â– Ed irted • © We are excited about this news and our transformation journey at Jazz Pharmaceuticals. Jazz and GW Pharmaceuticals plc are focused on developing life-changing medicines for people with serious diseases, often with limited or no treatment options. Patients are at the center of what each company does. Jazz’s and GW’s global teams possess unique talents ano expert se and have proven capability to develop and launch differentiated therapies to support often-overlooked patient populations. Both companies are purpose- ed and guided by shared values that induce integrity, collaboration, passion, innovation and pursuit of excellence, and have cultures where diversity, equity and inclusion are a priority. Important: https://lnkd.in/eG3NBjF Jazz Pharmaceuticals 63 269 followers + Follow 1d â– Edited - Today Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, a global leader in the science, development, manufacturing and commercialization of cannabinoid-based prescription medicines. ..see more We are joining two teams that mshare a passion for and track record of developing differentiated therapies that advance science and transform the lives of patients. This transaction will combine two global neuroscience companies both focused on critical, unmet f patient needs. Bruce Cozadd C hairman and Chief Etecutive Officer Jazz Pharmaceuticals Jazz Pharmaceuticals Read More investor.jazzpharma.com â– 14 min read